Passar para o conteúdo principal

Preclinical evaluation of PHH-1V candidate against SARS-CoV-2 in non-human primates

COVID-19

Prenafeta A, Bech-Sàbat G, Moros A, Barreiro A, Fernández A, Cañete M, et al. 

 

SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continuously striking with an unpredictable evolution. Despite the success in vaccine production and mass vaccination programs, the situation is not still completely controlled, and therefore accessible second-generation vaccines are required to mitigate the pandemic. We previously developed an adjuvanted vaccine candidate coded PHH-1V, based on a heterodimer fusion protein comprising the RBD domain of two SARS-CoV-2 variants. Here, we report data on the efficacy, safety, and immunogenicity of PHH-1V in cynomolgus macaques.